» Authors » Richard Womer

Richard Womer

Explore the profile of Richard Womer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 582
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Dubois S, Krailo M, Glade-Bender J, Buxton A, Laack N, Randall R, et al.
J Clin Oncol . 2023 Jan; 41(11):2098-2107. PMID: 36669140
Purpose: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to...
2.
Fox E, Busch C, DeBernardo A, Segers B, Gottschalk J, Womer R, et al.
Cancer Chemother Pharmacol . 2021 Mar; 87(6):807-815. PMID: 33677616
Purpose: High dose methotrexate (HDMTX) acute kidney injury (AKI) results in prolonged hospitalization and treatment delays. Using a pharmacologically-based approach, HDMTX was administered with standard combination therapy to patients with...
3.
Jain P, Surrey L, Straka J, Russo P, Womer R, Li M, et al.
Pediatr Blood Cancer . 2021 Feb; 68(6):e28933. PMID: 33565241
Pediatric histiocytic neoplasms are hematopoietic disorders frequently driven by the BRAF-V600E mutation. Here, we identified two BRAF gene fusions (novel MTAP-BRAF and MS4A6A-BRAF) in two aggressive histiocytic neoplasms. In contrast...
4.
Grewal A, Li Y, Grewal S, Bagatell R, Balamuth N, Womer R, et al.
J Pediatr Hematol Oncol . 2020 Feb; 42(5):e305-e309. PMID: 32079986
Background: The use of radiation therapy to treat metastases in patients with metastatic Ewing sarcoma (MES) has been controversial and variable. The authors report outcomes and patterns of failure after...
5.
Dirksen U, Brennan B, Le Deley M, Cozic N, van den Berg H, Bhadri V, et al.
J Clin Oncol . 2019 Sep; 37(34):3192-3202. PMID: 31553693
Purpose: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and...
6.
Hill-Kayser C, Tochner Z, Li Y, Kurtz G, Lustig R, James P, et al.
Int J Radiat Oncol Biol Phys . 2019 Feb; 104(2):401-408. PMID: 30738983
Purpose: Patients with high-risk neuroblastoma (HR-NBL) require radiation to the primary tumor site and sites of persistent metastatic disease. Proton radiation therapy (PRT) may promote organ sparing, but long-term outcomes...
7.
Fox E, Levin K, Zhu Y, Segers B, Balamuth N, Womer R, et al.
Oncologist . 2018 Feb; 23(7):762-e79. PMID: 29445029
Lessons Learned: Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole,...
8.
Vogel J, Both S, Kirk M, Chao H, Bagatell R, Li Y, et al.
Pediatr Blood Cancer . 2017 Oct; 65(2). PMID: 29058370
Purpose: Pediatric head and neck malignancies are managed with intensive multimodality therapy. Proton beam therapy (PBT) may reduce toxicity by limiting exposure of normal tissue to radiation. In this study,...
9.
Hill-Kayser C, Tochner Z, Both S, Lustig R, Reilly A, Balamuth N, et al.
Pediatr Blood Cancer . 2013 Jun; 60(10):1606-11. PMID: 23737005
Background: Proton therapy for treatment for high-risk neuroblastoma may offer sparing of organs at risk (OAR) when compared to intensity-modulated X-ray therapy (IMXT). Procedure: Double-scattered proton plans and IMXT plans...
10.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al.
J Clin Oncol . 2009 Apr; 27(15):2536-41. PMID: 19349548
Purpose: The Ewing sarcoma family of tumors (ESFT) is a group of malignant tumors of soft tissue and bone sharing a chromosomal translocation affecting the EWS locus. The Intergroup INT-0091...